Dr. Yee on Neoadjuvant Pertuzumab in HER2-Positive Breast Cancer
Dr. Osborne on Pertuzumab in HER2+ Breast CancerПодробнее
Dr. Tripathy on Neoadjuvant Treatment Strategies in HER2+ Breast CancerПодробнее
Dr. Yee on Neoadjuvant Therapy for Triple-Negative Breast CancerПодробнее
Dr Yee on Neoadjuvant Datopotamab Deruxtecan in High-Risk, Early-Stage Breast CancerПодробнее
Dr. Pegram on Pertuzumab Combination for HER2-Positive Breast CancerПодробнее
Dr. Peter Beitsch on Pertuzumab in the Luminal Subtype of HER2-Positive Breast CancerПодробнее
Dr. Hamilton Discusses Challenges With Approved Treatments for HER2-Positive Breast CancerПодробнее
Dr. Yee on Phase II ADAPT Trial Results for HER2+/HR+ Breast CancerПодробнее
Dr. Tolaney on the Neoadjuvant Therapy for HER2-Positive Breast CancerПодробнее
New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Bagegni & Dr. GradisharПодробнее
Dr. Pegram on Pertuzumab and Trastuzumab in Breast CancerПодробнее
Dr. Hudis on Neoadjuvant Treatment of HER2-Positive Breast CancerПодробнее
Neoadjuvant Therapy for HER2-positive Breast Cancer - Dr. Scott ChristensenПодробнее
Dr Yee on Neoadjuvant Datopotamab Deruxtecan Plus Durvalumab in Early-Stage Breast CancerПодробнее
Dr. Pegram on Challenges in Neoadjuvant Treatment for HER2-Positive Breast CancerПодробнее
Neoadjuvant Trastuzumab and Pertuzumab Plus Chemotherapy Versus T-DM1 and Pertuzumab in HER2 BreastПодробнее
Dr. Pegram on Neoadjuvant Treatments for HER2-Postive Breast CancerПодробнее
Breast Cancer: Adding Pertuzumab as a Neoadjuvant Treatment OptionПодробнее
Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HE...Подробнее
